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In drug development and drug licensing, it sometimes
occurs that a new drug did not demonstrate effectiveness
for the full study population, but there appears to be bene-
fit in a relevant subgroup. This raises the question how
strong the evidence from such a subgroup is in this situa-
tion, and which confirmatory testing strategies are the
most appropriate.
Using simulation studies, we compared the evolution
of the type I error rate and the power of several types of
confirmatory strategies, including replications of sub-
group findings in parallel or new studies. The primary
outcome was assumed to be continuous and normally
distributed.
In case of a single trial, the inflation of the overall type I
error is substantial, especially in relatively small subgroups
with the added risk of starting a replication trial that
should not be done. When the p-value for the subgroup of
interest is very small, i.e. below 0.001, the strength of evi-
dence is improved but such a strong result is not likely to
occur in case of an overall non-significant result. The level
of evidence improves as expected when subgroup findings
are replicated in (the design of) a new trial. In this situa-
tion, the overall type I error is very close to the theoretical
value, and almost guarantees its control.
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